Antiproliferative Effect of L1CAM-Specific Aptamers in Human Glioblastoma Cell Cultures

Glioblastoma remains an incurable form of brain tumor. Existing therapeutic methods can only produce slight prolongation of the lives of patients with this diagnosis. There is therefore a need to seek new approaches and develop new methods of treating glioblastoma. We describe here the principle of...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience and behavioral physiology 2024-08, Vol.54 (6), p.929-937
Main Authors: Kolesnikova, V. A., Mitina, A. K., Ryabova, A. V., Fab, L. V., Pronin, I. N., Pavlova, G. V.
Format: Article
Language:English
Subjects:
Aptamers
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Brain cancer
Brain tumors
Cell adhesion & migration
Cell culture
Cell proliferation
Glioblastoma
Glioblastoma cells
Glioma
Glioma cells
Kinases
Medical research
Neurobiology
Neurosciences
Original Research
Proteins
Stem cells
Tumor cells
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma remains an incurable form of brain tumor. Existing therapeutic methods can only produce slight prolongation of the lives of patients with this diagnosis. There is therefore a need to seek new approaches and develop new methods of treating glioblastoma. We describe here the principle of an approach to glioblastoma tumor cells which consists of targeted inhibition of the proliferation of L1CAM-positive cells using aptamers. L1CAM is regarded as a marker of gliomastem cells, whose presence in a tumor may be responsible for resistance to treatment. The studies reported here led to selection of the yly12 aptamer from a panel of aptamers for L1CAM; this aptamer was shown to have antiproliferative effects which were more powerful in the case of human glioblastoma cells with elevated L1CAM expression. Thus, this approach may solve the issue of glioblastoma cell resistance and prevent tumor recurrence by acting on glioma stem cells.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-024-01678-8